StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.86 | $0.85 | -1.37% | 0.2M |
| 05-12 | $0.86 | $0.87 | +1.49% | 0.1M |
| 05-13 | $0.88 | $0.85 | -3.59% | 0.2M |
| 05-14 | $0.85 | $0.85 | +0.59% | 0.2M |
| 05-15 | $0.86 | $0.82 | -4.65% | 0.6M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $563.00K | $1.12M | $885.00K | $619.00K |
Operating Income | $-3.47M | $-12.51M | $-8.99M | $-5.79M |
Net Income | $-3.52M | $-11.17M | $-8.23M | $-2.90M |
EPS (Diluted) | $-0.09 | $-0.32 | $-0.24 | $-0.16 |
Total Assets | $13.96M | $8.10M | $11.21M | $13.64M |
Total Liabilities | $2.70M | $2.67M | $3.13M | $3.00M |
Cash & Equivalents | $12.36M | $7.02M | $10.04M | $12.31M |
Free Cash Flow OCF − CapEx | $-3.71M | $-10.97M | $-7.96M | $-5.68M |
Shares Outstanding | 45.05M | 36.61M | 36.65M | 36.65M |
No sell-side coverage available for RNXT.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for RNXT.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.